Lantern Pharma Inc.

Lantern Pharma Inc. (LTRN) priced its initial public offering on Jun 12, 2020 at $15.00 per share, raising $26.2M. At the IPO price its market capitalization was about $93.3M. ThinkEquity was lead-left underwriter, joined by Paulson. Lewis Brisbois Bisgaard & Smith advised the company and Blank Rome advised the underwriters.

Lantern Pharma Inc. is a clinical-stage biotechnology company using artificial intelligence, machine learning and genomic data to streamline drug development and find patients likely to benefit from targeted oncology therapies. Its RADR platform includes more than 275 million data points, and its portfolio includes small molecules others previously failed to develop.

Status

IPO

Ticker

LTRN

Priced

Jun 12, 2020

IPO price

$15.00

Raised

$26.2M

Market cap at IPO price

$93.3M

First filed

Apr 16, 2020

Underwriters

ThinkEquity and Paulson

Company counsel

Lewis Brisbois Bisgaard & Smith

Underwriters' counsel

Blank Rome

Sector

Biotech & pharma

Country / state

TX

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.